DE60229854D1 - Test für zelluläre immunität mittels an einen festen träger gebundener peptide - Google Patents

Test für zelluläre immunität mittels an einen festen träger gebundener peptide

Info

Publication number
DE60229854D1
DE60229854D1 DE60229854T DE60229854T DE60229854D1 DE 60229854 D1 DE60229854 D1 DE 60229854D1 DE 60229854 T DE60229854 T DE 60229854T DE 60229854 T DE60229854 T DE 60229854T DE 60229854 D1 DE60229854 D1 DE 60229854D1
Authority
DE
Germany
Prior art keywords
peptides
test
cellular immunity
solid carrier
characterization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229854T
Other languages
English (en)
Inventor
Hanne Gahery-Segard
Jean-Gerard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE60229854D1 publication Critical patent/DE60229854D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60229854T 2001-08-27 2002-08-27 Test für zelluläre immunität mittels an einen festen träger gebundener peptide Expired - Lifetime DE60229854D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111136A FR2828934B1 (fr) 2001-08-27 2001-08-27 Test de l'immunite cellulaire par des peptides fixes sur support solide
PCT/FR2002/002937 WO2003019195A2 (fr) 2001-08-27 2002-08-27 Test de l'immunite cellulaire par des peptides fixes sur support solide

Publications (1)

Publication Number Publication Date
DE60229854D1 true DE60229854D1 (de) 2008-12-24

Family

ID=8866750

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229854T Expired - Lifetime DE60229854D1 (de) 2001-08-27 2002-08-27 Test für zelluläre immunität mittels an einen festen träger gebundener peptide

Country Status (11)

Country Link
US (2) US20060121537A1 (de)
EP (2) EP1421387B1 (de)
JP (1) JP4550414B2 (de)
AT (1) ATE414279T1 (de)
AU (1) AU2002341057A1 (de)
CA (1) CA2458986A1 (de)
DE (1) DE60229854D1 (de)
ES (1) ES2316620T3 (de)
FR (1) FR2828934B1 (de)
IL (1) IL160597A0 (de)
WO (1) WO2003019195A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29858A (id) 1998-11-04 2001-10-18 Isis Innovation Uji diagnostik tuberkulosis
PL202927B1 (pl) * 2003-07-20 2009-08-31 Carr Daniel R Peptyd i kompozycja farmaceutyczna oraz ich zastosowania medyczne
KR20070115871A (ko) 2004-12-23 2007-12-06 노보 노르디스크 에이/에스 항체 결합 친화 리간드
CN101124238A (zh) * 2004-12-23 2008-02-13 诺和诺德公司 结合抗体的亲和性配体
US8509187B2 (en) * 2008-03-21 2013-08-13 Koninklijke Philips N.V. Method for communicating and radio station therefor
CN101978764A (zh) * 2008-03-21 2011-02-16 皇家飞利浦电子股份有限公司 用于通信的方法和用于通信的无线电站
RU2464571C1 (ru) * 2011-06-17 2012-10-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения специфического клеточного иммунного ответа к антигенам вируса кори и краснухи
US20220187279A1 (en) * 2020-12-14 2022-06-16 Immunitybio, Inc. Rapid t-cell assay for sars-cov-2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5980899A (en) * 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
US5747265A (en) * 1992-10-30 1998-05-05 T Cell Diagnostics, Inc. Method for measuring the amount of a cell-associated molecule
US5595881A (en) * 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
EP0954601A4 (de) * 1996-03-20 2004-08-18 Genzyme Corp Verfahren zur erkennung von zytotoxischen t-zell epitopen
BR9713145A (pt) * 1996-11-27 2000-02-08 Eastman Chem Co Processo, composição absorvente de luz e compostos diácidos.
WO1999037313A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Immune effector cell hybrids
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie

Also Published As

Publication number Publication date
EP2037276A3 (de) 2009-06-10
EP1421387B1 (de) 2008-11-12
CA2458986A1 (fr) 2003-03-06
AU2002341057A1 (en) 2003-03-10
ES2316620T3 (es) 2009-04-16
US20080213818A1 (en) 2008-09-04
EP2037276A2 (de) 2009-03-18
ATE414279T1 (de) 2008-11-15
IL160597A0 (en) 2004-07-25
WO2003019195A3 (fr) 2004-01-22
EP1421387A2 (de) 2004-05-26
JP4550414B2 (ja) 2010-09-22
FR2828934A1 (fr) 2003-02-28
FR2828934B1 (fr) 2004-08-13
WO2003019195A2 (fr) 2003-03-06
JP2005501257A (ja) 2005-01-13
US20060121537A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
DK1210430T3 (da) MUC-1-afledte peptider
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
NO20011386L (no) Nye fremgangsmåter for fremvisning av (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
NO965592D0 (no) Nye peptider
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE60229854D1 (de) Test für zelluläre immunität mittels an einen festen träger gebundener peptide
CR8167A (es) Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
GB0215710D0 (en) Diagnostic method
DE60025704D1 (de) Das goodpasture-antigen bindende protein
ATE274190T1 (de) Methoden und kits zum sequenzieren von polypeptiden
ATE376184T1 (de) Epitop-untersuchung mit hla
DE50304961D1 (de) Pneumatisches hautelastizitätsmessgerät
IT1307864B1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
DE602004030824D1 (de) An der oberfläche befindliche campylobacter jejuni-polypeptide
IT1271486B (it) Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
SE0202702D0 (sv) Immunoassays for specific determination of SCCA isoforms
NO20022276D0 (no) Human neurokinin-B-forlöper fra placenta
WO2006023211A3 (en) Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof
DE69011879D1 (de) Immuntestverfahren für zelluläres Eiweiss.
WO2006060643A3 (en) Novel bladder matrix protein peptides and methods of detection of bladder cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition